Cargando…

Not All EGFR Exon 20 Insertions Are Created Equal

Detalles Bibliográficos
Autores principales:	Lin, Yen-Ting, Shih, Jin-Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474363/ https://www.ncbi.nlm.nih.gov/pubmed/34589951 http://dx.doi.org/10.1016/j.jtocrr.2020.100069

Ejemplares similares

Inhibition of EGFR Signaling: All Mutations Are Not Created Equal
por: Gazdar, Adi F, et al.
Publicado: (2005)

"ALL ANTIDEPRESSANTS ARE CREATED EQUAL" (SOME ARE MORE EQUAL THAN OTHERS)
por: Doongaji, Dinshaw R
Publicado: (2000)

Cytogenetic alterations in CML: not all created equal
por: Gong, Zimu, et al.
Publicado: (2018)

EGFR Testing Patterns and Detection of EGFR Exon 20 Insertions in the United States
por: Lin, Huamao M., et al.
Publicado: (2022)

Are all metachronous multifocal urothelial carcinoma created equal?
por: Reis, Leonardo O.
Publicado: (2018)

Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2023)

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
por: Murano, Chihiro, et al.
Publicado: (2019)

Structural Basis for the Functional Changes by EGFR Exon 20 Insertion Mutations
por: Tamirat, Mahlet Z., et al.
Publicado: (2021)

EGFR Exon 20 Insertion Mutations in Sinonasal Squamous Cell Carcinoma
por: Pacini, Laura, et al.
Publicado: (2022)

MicroRNA Based Treatment of Cardiomyopathy: Not all Dystrophies are Created Equal
por: Rodino‐Klapac, Louise R.
Publicado: (2013)

Not All Insults Are Created Equal for Awakening Dormant Stem Cell Abilities
por: Vega, Paige N., et al.
Publicado: (2019)

Not all vinculins are created equal
por: Leslie, Mitch
Publicado: (2014)

EGFR exon 20 insertion mutations in non-small cell lung cancer
por: Wang, Fenfang, et al.
Publicado: (2020)

Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer
por: Pacini, Laura, et al.
Publicado: (2021)

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
por: Zhang, Shannon S, et al.
Publicado: (2021)

Not all arrestins are created equal: Therapeutic implications of the functional diversity of the β-arrestins in the heart
por: Lymperopoulos, Anastasios, et al.
Publicado: (2019)

Not all nuclear pores created equal
por: Leslie, Mitch
Publicado: (2010)

All Purkinje cells are not created equal
por: Albergaria, Catarina, et al.
Publicado: (2014)

Not All Immune Checkpoints Are Created Equal
por: De Sousa Linhares, Annika, et al.
Publicado: (2018)

Not All Worms Were Created Equal
por: Loukas, Alex, et al.
Publicado: (2022)

Not all P waves are equally created
por: Qian, Xiaoxiao, et al.
Publicado: (2022)

Are all antibiotic persisters created equal?
por: Shultis, Michael W., et al.
Publicado: (2022)

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
por: Lin, Ling, et al.
Publicado: (2020)

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
por: Vyse, Simon, et al.
Publicado: (2019)

Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer
por: Gao, Xin, et al.
Publicado: (2020)

Clustered ERF Transcription Factors: Not All Created Equal
por: Yuan, Ling
Publicado: (2020)

EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios
por: Kobayashi, Ikei S., et al.
Publicado: (2021)

Relative Specificity: All Substrates Are Not Created Equal
por: Zeng, Yan
Publicado: (2014)

Reply: Not all incomplete revascularizations are created equal
por: Weiss, Aaron J., et al.
Publicado: (2021)

LBMON273 Not All Men Are Created Equal
por: van Rooyen, Desmaré, et al.
Publicado: (2022)

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2019)

Clinicopathologic and molecular characteristics of Chinese lung adenocarcinoma patients with EGFR exon 20 insertion mutations
por: Wang, Lifeng, et al.
Publicado: (2022)

Activity of tarloxotinib‐E in cells with EGFR exon‐20 insertion mutations and mechanisms of acquired resistance
por: Nishino, Masaya, et al.
Publicado: (2021)

Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer
por: Kian, Waleed, et al.
Publicado: (2022)

Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines
por: Olivier, Timothée, et al.
Publicado: (2022)

Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors
por: Qin, YanRu, et al.
Publicado: (2020)

Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations
por: Vasconcelos, Pedro E.N.S., et al.
Publicado: (2020)

The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations
por: Kagawa, Yosuke, et al.
Publicado: (2023)

EGFR exon 20 insertion mutation in advanced thymic squamous cell carcinoma: Response to apatinib and clinical outcomes
por: Yudong, Su, et al.
Publicado: (2018)

Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma: A case report
por: Inagaki, Yuji, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f1m03eqvscoplnls5l1d48tcre